Wetherby Asset Management Inc Bei Gene, Ltd. Transaction History

Wetherby Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$146.52 - $269.56 $217,142 - $399,487	-1,482 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $11,930 - $18,688	48 Added 3.35%	1,482 $401,000
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $12,230 - $19,753	-49 Reduced 3.3%	1,434 $520,000
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $23,712 - $29,727	81 Added 5.78%	1,483 $509,000
Q1 2021 May 14, 2021	BUY	$260.64 - $382.12 $49,782 - $72,984	191 Added 15.77%	1,402 $488,000
Q4 2020 Feb 11, 2021	BUY	$221.31 - $316.61 $259,154 - $370,750	1,171 Added 2927.5%	1,211 $313,000
Q3 2020 Dec 16, 2020	SELL	$189.18 - $286.44 $188,423 - $285,294	-996 Reduced 96.14%	40 $11,000
Q3 2020 Dec 16, 2020	SELL	$189.18 - $286.44 $10,026 - $15,181	-53 Reduced 4.87%	1,036 $297,000
Q3 2020 Nov 13, 2020	BUY	$189.18 - $286.44 $206,017 - $311,933	1,089 New	1,089 $312,000

249

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Wetherby Asset Management Inc with notifications on news.